Compare · NVO vs TRAW
NVO vs TRAW
Side-by-side comparison of Novo Nordisk A/S (NVO) and Traws Pharma Inc. (TRAW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRAW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 20244.1x TRAW ($10.7M).
- Over the past year, NVO is down 27.0% and TRAW is down 52.7% - NVO leads by 25.7 points.
- TRAW has been more active in the news (13 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for TRAW).
- Company
- Novo Nordisk A/S
- Traws Pharma Inc.
- Price
- $49.08-0.41%
- $0.71+5.96%
- Market cap
- $217.28B
- $10.7M
- 1M return
- +11.62%
- -44.10%
- 1Y return
- -27.00%
- -52.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TRAW
- SEC Form 4 filed by Chief Executive Officer Dukes Iain D.
- SEC Form 4 filed by Chief Medical Officer Redfield Robert
- SEC Form 4 filed by Chief Financial Officer Parker Charles Nolan
- SEC Form 4 filed by Director Shoemaker Mary Teresa
- SEC Form 4 filed by Director Clarke Trafford
- SEC Form 4 filed by Director Leaman John Harold
- Traws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Traws Pharma Inc.
- SEC Form EFFECT filed by Traws Pharma Inc.
- Traws Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits